Managers / Q4 2023 · view latest →
venBio Partners LLC
CIK 0001776382 · 1700 OWENS STREET, SUITE 595, SAN FRANCISCO, CA, 94158 · 415-522-0100
Summary
Venbio Partners LLC reported $667M in U.S.-listed holdings across 7 positions for Q4 2023.
The portfolio is heavily concentrated: Rayzebio alone accounts for 48.1% of reported value.
Compared with Q3 2023, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 73.3% · $489M
- Common Stock · 26.7% · $178M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VENTYX BIOSCIENCES INC | SOLD OUT | −758.8K | 0 | −$26M | $0 |
| PHARVARIS N V | ADDED | +654.8K | 4.92M | +$49M | $138M |
| RAYZEBIO INC | HELD | +0 | 5.16M | +$206M | $321M |
| ALXOALX ONCOLOGY HLDGS INC | HELD | +0 | 9.70M | +$98M | $144M |
| ACELYRIN INC | HELD | +0 | 3.85M | −$10M | $29M |
| IMPEL PHARMACEUTICALS INC | HELD | +0 | 2.76M | −$845,876 | $340,834 |
| HRMYHARMONY BIOSCIENCES HLDGS IN | HELD | +0 | 1.04M | −$486,636 | $33M |
| ELEVATION ONCOLOGY INC | HELD | +0 | 2.91M | −$366,030 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RAYZEBIO INC | COM | 48.06% | $321M | 5.16M |
| 2 | ALXOALX ONCOLOGY HLDGS INChistory → | COM | 21.65% | $144M | 9.70M |
| 3 | PHARVARIS N V | COM | 20.68% | $138M | 4.92M |
| 4 | HRMYHARMONY BIOSCIENCES HLDGS INhistory → | COM | 5.01% | $33M | 1.04M |
| 5 | ACELYRIN INC | COM | 4.31% | $29M | 3.85M |
| 6 | ELEVATION ONCOLOGY INC | COM | 0.23% | $2M | 2.91M |
| 7 | IMPEL PHARMACEUTICALS INC | COM | 0.05% | $340,834 | 2.76M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $281M | 6 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $216M | 6 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $176M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $115M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $124M | 7 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $171M | 7 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $194M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $232M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $282M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $667M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $353M | 8 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $276M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $323M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $432M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $351M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $451M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $555M | 9 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.0B | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $847M | 10 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.1B | 7 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $658M | 8 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $120M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $38M | 3 | May 26, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $233M | 6 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $211M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $212M | 6 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $116M | 4 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.